Personalis, Inc. (PSNL)
NASDAQ: PSNL · IEX Real-Time Price · USD
1.460
+0.060 (4.29%)
At close: May 20, 2024, 4:00 PM
1.470
+0.010 (0.68%)
After-hours: May 20, 2024, 5:31 PM EDT
Personalis Revenue
Personalis had revenue of $74.15M in the twelve months ending March 31, 2024, with 7.96% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $19.53M with 3.53% year-over-year growth. In the year 2023, Personalis had annual revenue of $73.48M with 12.97% growth.
Revenue (ttm)
$74.15M
Revenue Growth
+7.96%
P/S Ratio
1.01
Revenue / Employee
$332,493
Employees
223
Market Cap
75.83M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 73.48M | 8.43M | 12.97% |
Dec 31, 2022 | 65.05M | -20.45M | -23.92% |
Dec 31, 2021 | 85.49M | 6.85M | 8.70% |
Dec 31, 2020 | 78.65M | 13.44M | 20.61% |
Dec 31, 2019 | 65.21M | 27.43M | 72.62% |
Dec 31, 2018 | 37.77M | 28.38M | 302.15% |
Dec 31, 2017 | 9.39M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Silver Spike Investment | 2.77B |
P3 Health Partners | 1.35B |
Marinus Pharmaceuticals | 28.29M |
CollPlant Biotechnologies | 10.96M |
Asensus Surgical | 8.72M |
Serina Therapeutics | 3.15M |
PSNL News
- 3 days ago - Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 12 days ago - Personalis Reports First Quarter 2024 Financial Results - Business Wire
- 26 days ago - Personalis to Announce First Quarter 2024 Financial Results - Business Wire
- 7 weeks ago - Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference - Business Wire
- 7 weeks ago - Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting - Business Wire
- 7 weeks ago - Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring - Business Wire
- 2 months ago - Personalis Reports Fourth Quarter and Full Year 2023 Financial Results - Business Wire
- 3 months ago - Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results - Business Wire